Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HLA-A*2402 is one of the most prevalent HLA class I alleles in Asian populations and is common worldwide. It encodes a cell-surface glycoprotein that binds short peptides derived from intracellular proteins, presenting them to CD8+ cytotoxic T lymphocytes and thereby initiating adaptive immune responses. Its peptide-binding groove accommodates anchor residues at positions 2 and 9 of the bound peptide, with a pronounced preference for tyrosine and phenylalanine at position 2 and leucine or phenylalanine at position 9, which confers specificity for epitope recognition. HLA-A*2402 is extensively studied for its role in viral immunity, cancer immunotherapy (especially peptide-based vaccines and T-cell therapies), and transplant compatibility. The structure-function relationship of HLA-A*2402 determines immunodominance of presented epitopes and influences disease outcomes and therapeutic response.
Presentation of specific antigenic peptides to cytotoxic T lymphocytes, leading to T cell-mediated killing of target cells (e.g., tumor or infected cells)
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human leukocyte antigen A*2402 (HLA-A*2402).